BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 26104147)

  • 1. Experience with central venous access devices (CVADs) in the Canadian hemophilia primary prophylaxis study (CHPS).
    Langley AR; Stain AM; Chan A; McLimont M; Chait S; Wu J; Poon MC; Card R; Israels SJ; Laferriere N; Klaassen RJ; Rivard GE; Cloutier S; Hawes S; Feldman B; Blanchette V
    Haemophilia; 2015 Jul; 21(4):469-76. PubMed ID: 26104147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central venous access device-related infections in patients with haemophilia.
    Yeoh ZH; Furmedge J; Ekert J; Crameri J; Curtis N; Barnes C
    J Paediatr Child Health; 2013 Mar; 49(3):242-5. PubMed ID: 23438133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated analysis: central venous access device infection rates in an expanded cohort of paediatric patients with severe haemophilia receiving prophylactic recombinant tissue plasminogen activator.
    McCarthy CE; O'Brien M; Andrews J; Zoland JM; Macasiray E; Wong W; Lo C; Glader B; Tamaresis J; Jeng M
    Haemophilia; 2016 Jan; 22(1):81-6. PubMed ID: 26248602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central venous access devices for paediatric patients with haemophilia: a single-institution experience.
    Titapiwatanakun R; Moir C; Pruthi RK; Stavlo PL; Schmidt KA; Rodriguez V
    Haemophilia; 2009 Jan; 15(1):168-74. PubMed ID: 19149849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access.
    Nijdam A; Kurnik K; Liesner R; Ljung R; Nolan B; Petrini P; Fischer K;
    Haemophilia; 2015 Jul; 21(4):444-50. PubMed ID: 25582494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complications associated with central venous access device in children with haemophilia: a nationwide multicentre study in Finland.
    Vepsäläinen K; Lassila R; Arola M; Lähteenmäki P; Möttönen M; Mäkipernaa A; Riikonen P
    Haemophilia; 2015 Nov; 21(6):747-53. PubMed ID: 25832453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of the use of implantable venous access devices in the management of children with inherited bleeding disorders.
    Komvilaisak P; Connolly B; Naqvi A; Blanchette V
    Haemophilia; 2006 Dec; 12 Suppl 6():87-93. PubMed ID: 17123400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
    Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
    Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI after removal of central venous access device reveals a high number of asymptomatic thromboses in children with haemophilia.
    Ranta S; Kalajoki-Helmiö T; Pouttu J; Mäkipernaa A
    Haemophilia; 2012 Jul; 18(4):521-6. PubMed ID: 22176603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort.
    Feldman BM; Rivard GE; Babyn P; Wu JKM; Steele M; Poon MC; Card RT; Israels SJ; Laferriere N; Gill K; Chan AK; Carcao M; Klaassen RJ; Cloutier S; Price VE; Dover S; Blanchette VS
    Lancet Haematol; 2018 Jun; 5(6):e252-e260. PubMed ID: 29731369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central venous access device (CVAD) complications in Haemophilia with inhibitors undergoing immune tolerance induction: Lessons from the international immune tolerance study.
    Rodriguez V; Mancuso ME; Warad D; Hay CR; DiMichele DM; Valentino L; Kenet G; Kulkarni R
    Haemophilia; 2015 Sep; 21(5):e369-74. PubMed ID: 26178581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central venous access device infections in children with hemophilia: a comparison of prophylaxis and episodic therapy.
    Hacker MR; Page JH; Shapiro AD; Rich-Edwards JW; Manco-Johnson MJ
    J Pediatr Hematol Oncol; 2007 Jul; 29(7):458-64. PubMed ID: 17609623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Burden of illness and costs among paediatric haemophilia patients with and without central venous access devices treated in US hospitals.
    Buckley B; Dreyfus J; Prasad M; Gayle J; Kendter J; Hall E
    Haemophilia; 2018 May; 24(3):e93-e102. PubMed ID: 29577531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central venous access devices in haemophilia.
    Valentino LA; Ewenstein B; Navickis RJ; Wilkes MM
    Haemophilia; 2004 Mar; 10(2):134-46. PubMed ID: 14962202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central venous access device insertion and perioperative management of patients with severe haemophilia A: a local experience.
    Fonseca A; Nagel K; Decker K; Pukulakatt M; Pai M; Walton M; Chan AK
    Blood Coagul Fibrinolysis; 2016 Mar; 27(2):156-9. PubMed ID: 26340458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monthly recombinant tissue plasminogen activator administration to implantable central venous access devices decreases infections in children with haemophilia.
    Jeng MR; O'Brien M; Wong W; Zoland J; Lea J; Tang N; Glader B
    Haemophilia; 2009 Nov; 15(6):1272-80. PubMed ID: 19601989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central venous access catheters in children with haemophilia.
    Blanchette VS; al-Musa A; Stain AM; Filler RM; Ingram J
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S39-44. PubMed ID: 8735796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consensus recommendations for use of central venous access devices in haemophilia.
    Ewenstein BM; Valentino LA; Journeycake JM; Tarantino MD; Shapiro AD; Blanchette VS; Hoots WK; Buchanan GR; Manco-Johnson MJ; Rivard GE; Miller KL; Geraghty S; Maahs JA; Stuart R; Dunham T; Navickis RJ
    Haemophilia; 2004 Sep; 10(5):629-48. PubMed ID: 15357790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
    Dodd C; Watts RG
    Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of central venous access devices in children with haemophilia.
    Upadhyaya M; Richards M; Buckham S; Squire BR
    Pediatr Surg Int; 2009 Jun; 25(6):503-6. PubMed ID: 19455342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.